Gastrointestinal Tumors Clinical Trial
Official title:
A Multicenter, Open-label, Parallel Controlled, Prospective Cohort Study Evaluating Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors
Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related adverse reactions (including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis) in patients after two cycles of chemotherapy. The secondary endpoint indicators were: quality of life score (EORTC-QLQ-C30), nutritional risk score (PG-SGA, NRS2002), nutritional assessment indicators, changes in immune microenvironment, analysis of psychological status, survival time (1-year progression free survival rate), treatment tolerance (dose intensity, rate of treatment interruption, delay), etc.
Status | Recruiting |
Enrollment | 324 |
Est. completion date | December 31, 2024 |
Est. primary completion date | July 24, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Subjects voluntarily and sign an informed consent form; 2. Age = 18 years old and = 75 years old; 3. Patients with stage II-III gastrointestinal malignancies with clear pathological diagnosis and undergoing radical surgery 4. No adjuvant chemotherapy received after surgery 5. The Eastern Cancer Collaborative Group's Physical State Score (ECOG) is 0-2 points; 6. No contraindications to chemotherapy and the use of fluorouracil based chemotherapy regimens; Exclusion Criteria: 1. Allergy to the components of immune nutrients, allergic constitution, or other inability to eat; 2. Participated in other drug or food clinical trials within 2 months prior to enrollment; 3. Having a history of immune deficiency, including HIV testing positive, or having other acquired or congenital immune deficiency diseases, or having a history of organ transplantation, or active infections that are not suitable for chemotherapy (as determined by the researcher); 4. Subjects cannot guarantee compliance after participating in the study; 5. Other researchers believe that it is not suitable for enrollment. |
Country | Name | City | State |
---|---|---|---|
China | The First Hospital of China Medical University | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
China Medical University, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the incidence of chemotherapy related adverse reactions | including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis and so on. | the first two cycles of chemotherapy. (each cycle is 21 ± 3 days) | |
Secondary | quality of life score | EORTC(The European Organization for Reasearch and Treatment of Cancer)-QOL-C30 (Quality of Life Questionnare-Core 30), patients need to answer all the questions by circling the number (1,2,3,4), big number means the worse quality of life score | the first two cycles of chemotherapy. (each cycle is 21 ± 3 days) | |
Secondary | nutritional risk score | (PG-SGA) the patient-generated subjective global assessment. The result (A means well-nourished, B means middling-cacotrophia, C means severe malnutrition). Nutritional risk Screening Form 2002 (NRS2002), score =3 means patients with nutritional risk, score <3 patients with no nutritional risk. We use the two methods to evaluate the nutritional risk score. | the first two cycles of chemotherapy. (each cycle is 21 days) | |
Secondary | changes in immune microenvironment | cytokines (pg/ml) | the first two cycles of chemotherapy. (each cycle is 21 ± 3 days) | |
Secondary | survival time | 1-year progression free survival rate | 1-year | |
Secondary | treatment tolerance | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | the first two cycles of chemotherapy. (each cycle is 21 ± 3 days) | |
Secondary | changes in immune microenvironment | Intestinal flora changes | the first two cycles of chemotherapy. (each cycle is 21 ± 3 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05922358 -
Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT06152757 -
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
|
Early Phase 1 | |
Terminated |
NCT04171141 -
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
|
Phase 1 | |
Completed |
NCT01552291 -
The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies
|
Phase 4 | |
Active, not recruiting |
NCT03833700 -
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
|
Phase 1 | |
Completed |
NCT01640665 -
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
|
Phase 1 | |
Recruiting |
NCT04629326 -
PD-L1 Targeting Molecular Imaging of Solid Tumors
|
N/A | |
Recruiting |
NCT05981235 -
Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
|
Phase 1 | |
Recruiting |
NCT05262335 -
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
|
Phase 2 | |
Terminated |
NCT01648465 -
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06263205 -
Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques
|
N/A |